A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
Iraj Hosseini, Saroja Ramanujan(Unknown), Gautham K. Rao(Bristol-Myers Squibb (United States)), Jérémie Decalf, Travis W. Bainbridge(PDL BioPharma (United States)), Jennifer A. Getz(Denali Therapeutics (United States)), Kapil Gadkar(Sea Turtle Conservancy), Brett Fleisher(University of Florida), Amrita V. Kamath(Bristol-Myers Squibb (United States)), Meric Ovacik, Mandy Kwong, Christine Moussion(Centre National de la Recherche Scientifique)
Cited by 4
Related Papers
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
|Immunity|2005|317
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267
A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models
|Nature Neuroscience|2023|227
Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity
|ChemMedChem|2019|193